European Medicines Agency (EMA) starts rolling review of Janssen’s COVID-19 vaccine Ad26.COV2.S

Decision to start rolling review is based on early clinical studies in adults which suggest the vaccine triggers antibody production & immune cells that target coronavirus. Rolling review will continue until enough evidence is available for a marketing authorisation application.

Source:

European Medicines Agency